Illumina to divest cancer test maker Grail

Illumina says it will divest Grail following appeals court ruling

Illumina announced Sunday that it will offload cancer diagnostic test maker Grail, capping a two-year-long struggle with both US and ...

Illumina will divest Grail after losing battle with FTC. How did the San ...

San Diego biotech giant Illumina said Sunday that it is divesting Grail, the early cancer-detection company it acquired for roughly $7 billion.

Illumina Fined $476 Million For Acquiring Cancer Test Maker Grail ...

The record antitrust fine from the EU comes months after the FTC ordered the company to divest its $7.1 billion acquisition of Grail.

Don Levy on LinkedIn: Illumina to divest cancer test maker Grail after ...

Illumina to unwind $7B acquisition of Grail. Who closes a deal in that scenario - facing regulatory challenges in both the EU and US?

Grail bets big on flagship cancer test after spin-off from Illumina - Mint

US cancer diagnostic test maker Grail, which will list its shares on the Nasdaq on Tuesday after being spun out of Illumina, is betting that commercial ...

Fifth Circuit Largely Upholds FTC's Order In Illumina/Grail Case ...

The saga of DNA-sequencing firm Illumina's quest to acquire cancer detection-test maker Grail ended last month when the Fifth Circuit ...

Illumina to divest Grail if it loses US, EU court appeal - Medical Buyer

Illumina Inc said on Wednesday it will divest cancer test maker Grail as expeditiously as possible if the life sciences company loses either ...

Illumina vows to pursue Grail purchase despite FTC challenge

... cancer screening test, which is set to commercially launch this year. Illumina said in a news release that it will pursue its right to ...

Illumina to unwind $8B deal to acquire Grail, will divest holdings

Gene sequencing company Illumina Inc. this weekend announced it was divesting from Bay Area cancer diagnostic test maker Grail. For more ...

Amicus Brief - Illumina Inc. and Grail Inc. vs FTC

“Instead of Grail continuing to compete in the [multi-cancer early detection ... makers of MCED tests. Following the acquisition of Grail ...

Illumina announces completion of Grail spin-off

Biotechnology company Illumina has announced the completion of its spin-off of cancer test-maker Grail, which is now an independent entity.

When Bad Antitrust Costs Lives: The Illumina/GRAIL Tragedy

... Illumina Inc. to divest GRAIL Inc., makers of a multi-cancer early detection (MCED) test. The FTC claims that this vertical merger would ...

EU Approves Illumina's Divestment Plan for Grail After Two-Year Battle

... divestment of cancer diagnostic test maker Grail. According to a report by Reuters, Illumina's plan to divest Grail has been given the green ...

Illumina Plans to Divest Grail After US Antitrust Ruling - Bloomberg

Connecting decision makers ... after a US appeals court found that its $7 billion acquisition of the cancer detection startup violated antitrust ...

Grail bets big on flagship cancer test after spin-off from Illumina - KFGO

By Julie Steenhuysen CHICAGO (Reuters) - U.S. cancer diagnostic test maker Grail, which will list its shares on the Nasdaq on Tuesday after ...

When Bad Antitrust Costs Lives: The Illumina/GRAIL Tragedy

DNA-sequencing provider Illumina Inc. to divest GRAIL Inc., makers of a multi-cancer early detection (MCED) test.

FTC Orders Illumina To Divest GRAIL - The National Law Review

Opinion of the Commission, supra note 01, at 25. Id. at 76. See FTC Orders Illumina to Divest Cancer Detection Test Maker GRAIL to Protect ...

Illumina Announces Decision to Divest GRAIL (Press release) - Reddit

Illumina sells sequencers. Grail is the first mover/first in the industry for multi cancer detection tests. In order to operate they need sequencers/illumina ...

FTC aims to thwart Illumina's multibillion-dollar quest for Grail

... test makers. Therein lies ... Cancer competitors diagnostic tests mergers and acquisitions screening FTC Grail Illumina Diagnostics MedTech ...

UK won't order Grail's cancer test for 1M people this year, a setback ...

... Grail's cancer test to one million people, a setback for Illumina and its plan to divest the diagnostics company this year. On Wednesday ...